

## Title (en)

COMPOSITIONS AND METHODS FOR L-NUCLEOSIDES, L-NUCLEOTIDES, AND THEIR ANALOGS

## Title (de)

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR HERSTELLUNG VON L-NUCLEOSIDEN, L-NUCLEOTIDEN UND IHREN ANALOGA

## Title (fr)

COMPOSITIONS ET PROCEDES RELATIVES A DES NUCLEOSIDES-L, A DES NUCLEOTIDES-L AINSI QU'A LEURS ANALOGUES

## Publication

**EP 1244356 A4 20030319 (EN)**

## Application

**EP 00988189 A 20001219**

## Priority

- US 0034605 W 20001219
- US 17209799 P 19991223
- US 17344699 P 19991229
- US 17511100 P 20000106
- US 19075800 P 20000320
- US 22694700 P 20000822
- US 22687500 P 20000822
- US 23382100 P 20000919
- US 23382300 P 20000919
- US 23354800 P 20000919
- US 23382200 P 20000919
- US 23546500 P 20000926

## Abstract (en)

[origin: WO0145509A1] Nucleoside and nucleotide compounds and their analogs/prodrugs are provided. Particularly contemplated compounds include 1- beta -L-ribofuranosyl-1,2,4-triazole-3-carboxamide, which may be modified and/or phosphorylated. Contemplated compounds may further be combined with other pharmacological compounds, especially including Ribavirin, antibodies, and cytokines. Preferred uses of contemplated compounds include use as an antiviral compound, anti-inflammatory compound, antineoplastic compound, and as a compound to stimulate cellular growth.

## IPC 1-7

**A01N 43/04; A61K 31/70; C07H 19/00; C07H 19/04; C07H 19/044; C07H 19/056; A61K 39/42**

## IPC 8 full level

**C07H 19/056** (2006.01); **A01N 43/72** (2006.01); **A61K 31/70** (2006.01); **A61K 31/7056** (2006.01); **A61K 38/21** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61P 1/16** (2006.01); **A61P 25/00** (2006.01); **A61P 31/12** (2006.01); **A61P 31/16** (2006.01); **A61P 31/18** (2006.01); **A61P 37/02** (2006.01); **A61P 43/00** (2006.01); **C07H 19/12** (2006.01)

## IPC 8 main group level

**A61P 29/00** (2006.01); **A61P 35/00** (2006.01)

## CPC (source: EP KR)

**A01N 43/72** (2013.01 - EP); **A61K 31/70** (2013.01 - EP); **A61K 31/7056** (2013.01 - EP); **A61K 39/395** (2013.01 - EP); **A61P 1/16** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/12** (2017.12 - EP); **A61P 31/16** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07H 19/056** (2013.01 - KR); **C07H 19/12** (2013.01 - EP)

## C-Set (source: EP)

1. **A61K 31/70 + A61K 2300/00**
2. **A61K 31/7056 + A61K 2300/00**
3. **A61K 39/395 + A61K 2300/00**

## Citation (search report)

- [X] WO 9204381 A1 19920319 - SCOTGEN LTD [GB]
- [Y] WO 9816186 A2 19980423 - ICN PHARMACEUTICALS [US], et al
- [X] US 3798209 A 19740319 - WITKOWSKI J, et al
- [XY] EP 0956861 A1 19991117 - SCHERING CORP [US]
- [XY] WO 8705807 A1 19871008 - GRUBER HARRY EDWARD
- [XPY] WO 0030656 A1 20000602 - SALK INST FOR BIOLOGICAL STUDI [US], et al
- [Y] EP 0707855 A2 19960424 - SCHERING CORP [US]
- [XY] J. BALZARINI, C.K. LEE, P. HERDEWIJN, E. DE CLRECQ: "Mechanism of the potentiating effect of Ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficient virus", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 32, 1991, USA, pages 21509 - 21514, XP002227433
- [XY] GIUSEPPINA DI STEFANO, CORRADO BUSI, ALESSANDRO MATTIOLI, LUIGI FIUME: "Selective Delivery to the Liver of Antiviral Nucleoside Analogs Coupled to a High Molecular Mass Lactosaminated Poly-L-Lysine and Administered to Mice by Intramuscular Route", BIOCHEMICAL PHARMACOLOGY, vol. 49, no. 12, 1995, UK, pages 1769 - 1775, XP002227434
- [X] ROBERTO FERNANDEZ-LARSSON, JEAN L. PATTERSON: "Ribavirin is an inhibitor of Human Immunodeficiency Virus Reverse Transcriptase", MOLECULAR PHARMACOLOGY, vol. 38, no. 6, 1990, USA, pages 766 - 770, XP009003959
- [XY] GABRIELSEN, BJARNE ET AL: "Synthesis and antiviral evaluation of N-carboxamidine-substituted analogs of 1-.beta.-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride.", JOURNAL OF MEDICINAL CHEMISTRY (1992), 35(17), 3231-8, 1992, XP002227435
- [X] JAHRLING P B ET AL: "ENHANCED TREATMENT OF LASSA FEVER BY IMMUNE PLASMA COMBINED WITH RIBAVIRIN IN CYNOMOLGUS MONKEYS", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 149, no. 3, 1 March 1984 (1984-03-01), pages 420 - 427, XP002030799, ISSN: 0022-1899
- See references of WO 0145509A1

## Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

## DOCDB simple family (publication)

**WO 0145509 A1 20010628**; AU 2442201 A 20010703; BR 0016162 A 20020813; CA 2384326 A1 20010628; CN 1420723 A 20030528; CZ 20022112 A3 20030514; EP 1244356 A1 20021002; EP 1244356 A4 20030319; HK 1049944 A1 20030606; HR P20020485 A2 20051031; HU P0300219 A2 20030628; HU P0300219 A3 20050728; IL 148514 A0 20020912; JP 2003523957 A 20030812; KR 20030032908 A 20030426; MX PA02006251 A 20030128; NO 20022969 D0 20020620; NO 20022969 L 20020620; NZ 517634 A 20040625; PL 364927 A1 20041227; SI 20976 A 20030228; SK 8612002 A3 20030304; YU 47802 A 20060303

DOCDB simple family (application)

**US 0034605 W 20001219**; AU 2442201 A 20001218; BR 0016162 A 20001219; CA 2384326 A 20001219; CN 00817416 A 20001219; CZ 20022112 A 20001219; EP 00988189 A 20001219; HK 03102255 A 20030328; HR P20020485 A 20020603; HU P0300219 A 20001219; IL 14851400 A 20001219; JP 2001546256 A 20001219; KR 20027008069 A 20020621; MX PA02006251 A 20001219; NO 20022969 A 20020620; NZ 51763400 A 20001219; PL 36492700 A 20001219; SI 200020047 A 20001219; SK 8612002 A 20001219; YU P47802 A 20001219